Close menu

October 11th, 2021 | 11:30 CEST

Allianz, wallstreet:online, Commerzbank - Quo vadis stock markets?

  • Investments
Photo credits:

The markets are highly nervous at the moment. First, the Corona numbers went up again, then the Chinese real estate giant Evergrande was on the verge of collapse, and the supply chains are still not back in step. The result was falling indexes. That automatically leads to more fear, as the Fear and Greed Index also showed. Last week, the market calmed down slightly, and the fear index dropped from 27 to 34 points. In Germany, there is also the fact that more people have dabbled in equity investments due to a lack of interest rates. According to the Global Wealth Report, the purchase of securities grew by 65%. Many of the newly added shareholders know only rising stock markets. Consolidation would not hurt the market. On the other hand, there is hardly any alternative to investing money at the moment. It remains exciting.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    Allianz - Claim for damages still weighs heavily

    Allianz is Europe's largest insurance group, which currently has precisely one problem: the liquidation of two funds of its subsidiary Allianz Global Investors. A lawsuit for damages of about USD 6 billion is pending against this. It is unclear how long the legal dispute will last, but the Group has set aside a provision for the worst-case scenario. A conviction would eat up a large part of the annual profit. That is arguably the main reason the share price hit a new low for the year in September.

    Yet Allianz's business is doing well. Revenue grew 10.9% year-on-year in the second quarter of 2021. Quarterly net income per shareholder even climbed by 45.7%. On September 30, Allianz Swiss sold a life insurance package to Resolution RE in Switzerland. Allianz Direct is being launched in Spain, and motor vehicle insurance is to be sold there. Allianz Direct takes over the existing contracts of Fenix Directo. With the direct insurance business, the Company wants to become the fastest and most efficient insurance company.

    If you look at the share, it currently offers a dividend yield of just under 5%. It is rare to find an industry leader at a price-to-earnings (P/E) ratio of just over 10. The price-to-book ratio of about 1 is also very favorably valued. Management has also hinted at share buybacks. The business is growing, as already pointed out. One should wait for the verdict in the damages case to make an investment decision. If the judgment is favorable, the stock has potential.

    wallstreet:online - Smartbroker grows and gets an app

    wallstreet:online has long stood for the website of a large financial community. It also includes other financial portals such as, and But the seasonal advertising business was not enough for the Company, and so it added Smartbroker, a neobroker. This business unit is expected to overtake the old advertising business in the long term. The Group now owns 95% of wallstreet:online capital AG, the operator of Smartbroker.

    The half-year figures speak for themselves. Sales increased by 57% to EUR 23.8 million year-on-year. Thus in the first half-year, 69,000 new Smartbroker customers were won. There are now a total of 142,000 customers with assets of EUR 6.8 billion. Page impressions of the web portals also increased in the first half of the year by 37% to around 2.3 billion page impressions. Only EBITDA declined to EUR 0.6 million due to special costs and customer acquisitions. However, these are only one-off effects.

    The Company applied for a securities institution license in July. If the license is granted, the Company will drive forward the dovetailing of broker and financial portals even more effectively. To this end, Stefan Fischer, Dietmar Gabor and Christian Wendrock-Prechtl have been brought on board. A smartphone app is to be available at the beginning of 2022. In contrast to the competition, the share has held up quite well and is currently trading at EUR 23.50. In June, the institutions had still bought shares at EUR 26. The analysts at GBC arrive at a price target of EUR 37.70.

    Commerzbank - Possible positive signals

    Rumors are swirling around Commerzbank about the exit of the German government. According to media reports, the majority shareholder Cerberus has offered the German government a takeover of the share package. The federal government currently holds around 15% of Commerzbank. As the FDP has been arguing for a federal exit for some time and is now most likely to be part of a government, things could move quickly. Cerberus would benefit because the federal government's stake acts as a brake. Moreover, the timing would be optimal, as interest rates in America are expected to rise. Commerzbank is seen as one of the primary beneficiaries in this case, should the interest rate turnaround also spill over into Europe.

    While the stock has underperformed the market, rising interest rates would mean a boost for the bank. In addition to the interest rate factor and privatization, the bank's transformation could bring other positives. As an interested investor, one should note November 4, as the figures for the third quarter will be presented then, and there may be further information on the corporate transformation.

    What is currently certain is the discontinuation of the insurance platform, which was operated in cooperation with JDC. In the future, Commerzbank intends to offer only Allianz insurance policies. The share successfully defended the EUR 5 mark on September 20 and rose from there to currently EUR 6.25. The investment bank analysts at Kepler Cheuvreux have raised the price target from EUR 6.90 to EUR 7.50. According to the study, a doubling of the price is even possible.

    The current market trend is difficult to assess. There is hardly any alternative to investing in shares, especially since one can go bargain hunting here. The dividend yield speaks for Allianz. Currently, the claim for damages is a burden, but parts of it are already priced into the share. wallsteet:online has exponential growth, and the boards have already bought at higher prices. So they clearly believe in their Company. At Commerzbank, there are still many unanswered questions that the Company cannot directly influence. Are interest rates rising? Here, one should wait until something is ready to be announced.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...


    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.


    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.